Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1403-1413

  Selhorst, Philippe ^a,c   Vazquez, Ana C ^b   Terrazas Aranda, Katty ^a,e   Michiels, Johan ^a   Vereecken, Katleen ^a   Heyndrickx, Leo ^a   Weber, Jan ^b   Quiñones Mateu, Miguel E ^b   Ariën, Kevin K ^a   Vanham, Guido ^a,c,d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Quidel Corporation   (United States)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSIDAD MAYOR DE SAN ANDRÉS   (Bolivia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DAPIVIRINE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LERSIVIRINE; LOPINAVIR; MICROBICIDE; MIV 160; MIV 170; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RECOMBINANT PROTEIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THIOCARBOXANILIDE; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG SENSITIVITY; GENETIC RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIROGENESIS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANILIDES; ANTI-INFECTIVE AGENTS; BENZOXAZINES; CELL LINE; CELLS, CULTURED; DELAVIRDINE; DRUG RESISTANCE, VIRAL; FURANS; GENOTYPE; HIV-1; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79953049919     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01426-10     Document Type: Article

References (89)

1. Alliance for Microbicide Development. 2009. Microbicide and PreP candidates in ongoing clinical trials as of September 2009. Alliance for Microbicide Development, Silver Spring, MD. www.microbicide.org.
2. Andries, K., et al. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
3. Archer, R. H., et al. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J. Virol. 74:8390-8401. (Pubitemid 30666690)
4. Asahchop, E. L., et al. 2010. In vitro selection of novel etravirine-associated resistance mutations in B and non-B HIV-1 subtypes. Antivir. Ther. 15:A134.
5. Azijn, H., et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
6. Balzarini, J., and L. Van Damme. 2005. Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ 172:461-464.
7. Balzarini, J., and L. Van Damme. 2007. Microbicide drug candidates to prevent HIV infection. Lancet 369:787-797. (Pubitemid 46335821)
8. Beirnaert, E., et al. 1998. Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay. J. Virol. Methods 73:65-70. (Pubitemid 28473234)
9. Buckheit, R. W., M. Hollingshead, S. Stinson, and J. P. Bader. 1997. Efficacy, pharmacokinetics and in vivo anti-HIV activity of UC781. Antiviral Res. 34:62.
10. Buckheit, R. W., Jr., et al. 1997. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitorresistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:831-837.
11. Collins, J. A., et al. 2004. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. 78:603-611. (Pubitemid 38067582)
12. Cranage, M., et al. 2008. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5:e157.
13. Cutler, B., and J. Justman. 2008. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8:685-697.
14. D'Cruz, O. J., and F. M. Uckun. 2006. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemother. 57:411-423.
15. de Bethune, M.-P. 2009. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 85:75-90.
16. de Mendoza, C., et al. 2004. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. Clin. Infect. Dis. 39:1231-1238.
17. Devereux, H. L., V. C. Emery, M. A. Johnson, and C. Loveday. 2001. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J. Med. Virol. 65:218-224.
18. Djabarouti, S., et al. 2006. Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). J. Antimicrob. Chemother. 58:1090-1093.
19. Dudley, D. M., et al. 2009. A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques 46:458-467.
20. Dykes, C., et al. 2001. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 285:193-203. (Pubitemid 32641881)
21. Elinder, M., et al. 2010. Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism - importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem. Pharmacol. 80:1133-1140.
22. Fernández-Romero, J. A., et al. 2007. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex. Transm. Dis. 34:9-14.
23. Fletcher, P., et al. 2009. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 53:487-495.
24. Gali, Y., et al. 2010. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J. Virol. Methods 165:186-197.
25. Gatanaga, H., A. Hachiya, S. Kimura, and S. Oka. 2006. Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure. Virology 344:354-362. (Pubitemid 43049623)
26. Global Campaign for Microbicides. 2009. Microbicide trial results signal end of one chapter, focus turns to promising ARV-based candidates. Global Campaign for Microbicides, Washington, DC. http://www.global-campaign.org/ MDP301.htm.
27. Guay, L. A., et al. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802. (Pubitemid 29415583)
28. Gupta, S., et al. 2010. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother. 54:1973-1980.
29. Högberg, M., et al. 1999. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J. Med. Chem. 43:304.
30. Hossain, M. M., and M. A. Parniak. 2006. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1. J. Virol. 80:4440-4446.
31. Iglesias-Ussel, M. D., C. Casado, E. Yuste, I. Olivares, and C. Lopez-Galindez. 2002. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J. Gen. Virol. 83:93-101.
32. Jallow, S., et al. 2009. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J. Clin. Microbiol. 47:2200-2208.
33. Jallow, S., et al. 2007. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J. Clin. Microbiol. 45:1565-1571.
34. Johnson, J. A., et al. 2005. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192:16-23.
35. Karim, Q. A., et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
36. Kiptoo, M., et al. 2008. Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in North Rift Kenya. AIDS Res. Hum. Retroviruses 24:1555-1559.
37. Koval, C. E., C. Dykes, J. Wang, and L. M. Demeter. 2006. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology 353:184-192.
38. Lai, M.-T., et al. 2010. Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 54:4812-4824.
39. Lederman, M. M., R. E. Offord, and O. Hartley. 2006. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6:371-382.
40. Madan, R. P., M. J. Keller, and B. C. Herold. 2006. Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides. Curr. Opin. Infect. Dis. 19:49-54.
41. Maiga, A. I., et al. 2009. Resistance-associated mutations to etravirine (TMC-125) in Antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 54:728-733.
42. Martinez, J., P. Coplan, and M. A. Wainberg. 2006. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res. 71:343-350.
43. Muro, E. P., et al. 2005. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J. Acquir. Immune Defic. Syndr. 39:419-421.
44. Nel, A., et al. 2009. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:416-423.
45. Njai, H. F., et al. 2006. The predominance of human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02 (CRF02-AG) in West Central Africa may be related to its replicative fitness. Retrovirology 3:40.
46. Nuttall, J. P., et al. 2008. Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. Antimicrob. Agents Chemother. 52:909-914.
47. Patton, D. L., et al. 2007. Preclinical safety assessments of UC781 antihuman immunodeficiency virus topical microbicide formulations. Antimicrob. Agents Chemother. 51:1608-1615.
48. Prajapati, D. G., R. Ramajayam, M. R. Yadav, and R. Giridhar. 2009. The search for potent, small molecule NNRTIs: a review. Bioorg. Med. Chem. 17:5744-5762.
49. Puthanakit, T., P. Tanpaiboon, L. Aurpibul, T. R. Cressey, and V. Sirisanthana. 2009. Plasma efavirenz concentrations and the association with CYP2B6-516G>T polymorphism in HIV-infected Thai children. Antivir. Ther. 14:315-320.
50. Quinones-Mateu, M. E., and E. J. Arts. 2002. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist. Updat. 5:224-233.
51. Quinones-Mateu, M. E., and E. J. Arts. 2006. Virus fitness: concept, quantification, and application to HIV population dynamics. Curr. Top. Microbiol. Immunol. 299:83-140.
52. Quiñones-Mateu, M. E., and E. J. Arts. 2001. HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution, p. 134-170. In C. Kuiken et al. (ed.), HIV sequence compendium. Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
53. Quinones-Mateu, M. E., et al. 2000. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 74:9222-9233.
54. Quiñones-Mateu, M. E., D. M. Moore-Dudley, O. Jegede, and J. Weber. 2008. Viral drug resistance and fitness. Adv. Pharmacol. 56:257-296.
55. Quiñones-Mateu, M. E., J. Weber, H. R. Rangel, and B. Chakraborty. 2001. HIV-1 fitness and antiretroviral drug resistance. AIDS Rev. 3:223-242. (Pubitemid 34464228)
56. Read, T. R. H., et al. 2009. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 23:2222-2223.
57. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
58. Reuman, E. C., S.-Y. Rhee, S. P. Holmes, and R. W. Shafer. 2010. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Antimicrob. Chemother. 65:1477-1485.
59. Rhee, S.-Y., et al. 2003. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31:298-303. (Pubitemid 36150389)
60. Rhee, S. Y., et al. 2006. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 103:17355.
61. Romano, J., et al. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25:483-488.
62. Sahlberg, C., and X.-X. Zhou. 2008. Development of non-nucleoside reverse transcriptase inhibitors for anti-HIV therapy. Antiinfect. Agents Med. Chem. 7:101-117.
63. Schwartz, J., et al. 2008. Preliminary results from a pharmacokinetic study of the candidate vaginal microbicide agent 1% tenofovir gel, abstr. BO11-610. Microbicides 2008 Conference, New Dehli, India.
64. Schwartz, J. L., et al. 2008. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35:414-419.
65. Shafer, R. W. 2006. Rationale and uses of a public HIV drug-resistance database. J. Infect. Dis. 194:S51-S58.
66. Shekelle, P., et al. 2007. Antiretroviral (ARV) drug resistance in the developing world. Evid. Rep. Technol. Assess. (Full Rep.) 2007:1-74.
67. Skoler-Karpoff, S., et al. 2008. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebocontrolled trial. Lancet 372:1977-1987.
68. Smith, R. J., E. N. Bodine, D. P. Wilson, and S. M. Blower. 2005. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 19:413-421.
69. Su, G., et al. 2007. In vitro selection and characterization of viruses resistant to R1206, a novel non-nucleoside reverse transcriptase inhibitor. Antivir. Ther. 12:S35.
70. Tao, W., C. Richards, and D. Hamer. 2008. Enhancement of HIV infection by cellulose sulfate. AIDS Res. Hum. Retroviruses 24:925-929.
71. Terrazas-Aranda, K., Y. Van Herrewege, P. J. Lewi, J. Van Roey, and G. Vanham. 2007. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antivir. Chem. Chemother. 18:141-151.
72. Turner, D. M. D., et al. 2004. Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37:1627-1631.
73. UNAIDS. 2009. AIDS epidemic update: November 2009. UNAIDS/09.36E/JC1700E. UNAIDS, Geneva, Switzerland.
74. Van Damme, L., et al. 2008. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359:463-472.
75. Van Herrewege, Y., et al. 2004. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339.
76. Veazey, R. S., et al. 2005. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438:99-102. (Pubitemid 41599827)
77. Vergne, L., et al. 2002. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J. Acquir. Immune Defic. Syndr. 29:165-168.
78. Vingerhoets, J., et al. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782. (Pubitemid 41433197)
79. Vingerhoets, J., et al. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24:503.
80. Vyankandondera, J., et al. 2009. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 23:1531-1538.
81. Weber, J., et al. 2003. A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J. Gen. Virol. 84:2217-2228.
82. Weber, J., et al. 2010. Resistance analysis to maturation, protease, reverse transcriptase and integrase inhibitors based on 3′Gag(p2/p7/p1/p6) /PR/RT/INT-recombinant viruses: a useful tool in the multi-target era of antiretroviral drugs. Antivir. Ther. 14:A127.
83. Weber, J., et al. 2010. Resistance mutations in protease, reverse transcriptase, and integrase genes: do they have an epistatic effect on drug susceptibility and/or HIV-1 replicative fitness? Antivir. Ther. 15:A94.
84. Weber, J., et al. 2006. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J. Virol. Methods 136:102-117. (Pubitemid 44051582)
85. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
86. Wilson, D. P., P. M. Coplan, M. A. Wainberg, and S. M. Blower. 2008. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc. Natl. Acad. Sci. U. S. A. 105:9835-9840.
87. Xu, H.-T., et al. 2010. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob. Agents Chemother. 54:2401-2408.
88. Yerly, S., et al. 2004. Infrequent transmission of HIV-1 drug-resistant variants. Antivir. Ther. 9:375-384.
89. Zhang, Z., et al. 2007. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 51:429-437.